Cargando…

Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma

The activation of the stimulating factor of the interferon gene (STING) pathway can enhance the immune response within the tumor. Cyclic diguanylate monophosphate (c-di-GMP) is a negatively charged, hydrophilic STING agonist, however, its effectiveness is limited due to the poor membrane permeabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ziyuan, Liu, Juan, Xiao, Min, Zhang, Quanfeng, Liu, Zhonghua, Liu, Meiyan, Zhang, Peng, Zeng, Youlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tsinghua University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643898/
https://www.ncbi.nlm.nih.gov/pubmed/36405984
http://dx.doi.org/10.1007/s12274-022-5102-z
_version_ 1784826622266834944
author Zhang, Ziyuan
Liu, Juan
Xiao, Min
Zhang, Quanfeng
Liu, Zhonghua
Liu, Meiyan
Zhang, Peng
Zeng, Youlin
author_facet Zhang, Ziyuan
Liu, Juan
Xiao, Min
Zhang, Quanfeng
Liu, Zhonghua
Liu, Meiyan
Zhang, Peng
Zeng, Youlin
author_sort Zhang, Ziyuan
collection PubMed
description The activation of the stimulating factor of the interferon gene (STING) pathway can enhance the immune response within the tumor. Cyclic diguanylate monophosphate (c-di-GMP) is a negatively charged, hydrophilic STING agonist, however, its effectiveness is limited due to the poor membrane permeability and low bioavailability. Herein, we introduced KL-7 peptide derived from Aβ amyloid fibrils that can self-assemble to form nanotubes to load and deliver c-di-GMP, which significantly enhanced c-di-GMP’s effectiveness and then exhibited a robust “in situ immunity” to kill melanoma cells. KL-7 peptide nanotube, also called PNT, was loaded with negatively charged c-di-GMP via electrostatic interaction, which prepared a nanocomposite named c-di-GMP-PNT. Treatment of RAW 264.7 cells (leukemia cells in mouse macrophage) with c-di-GMP-PNT markedly stimulated the secretion of IL-6 and INF-β along with phospho-STING (Ser365) protein expression, indicating the activation of the STING pathway. In the unilateral flank B16-F10 (murine melanoma cells) tumor-bearing mouse model, compared to PNT and c-di-GMP, c-di-GMP-PNT can promote the expression of INF-β, TNF-α, IL-6, and IL-1β. At the same time, up-regulated CD4 and CD8 active T cells kill tumors and enhance the immune response in tumor tissues, resulting in significant inhibition of tumor growth in tumor-bearing mice. More importantly, in a bilateral flank B16-F10 tumor model, both primary and distant tumor growth can also be significantly inhibited by c-di-GMP-PNT. Moreover, c-di-GMP-PNT demonstrated no obvious biological toxicity on the main organs (heart, liver, spleen, lung, and kidney) and biochemical indexes of mice. In summary, our study provides a strategy to overcome the barriers of free c-di-GMP in the tumor microenvironment and c-di-GMP-PNT may be an attractive nanomaterial for anti-tumor immunity. [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material (synthesis and characterization of KL-7 peptide; the encapsulation rate and cumulative release rate of c-di-GMP-PNT; cytotoxicity of PNT, c-di-GMP, and c-di-GMP-PNT; anti-tumor effect of c-di-GMP-PNT (equivalent to 1 and 5 µg c-di-GMP per mouse); representative immunofluorescence images; and biosafety analysis) is available in the online version of this article at 10.1007/s12274-022-5102-z.
format Online
Article
Text
id pubmed-9643898
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Tsinghua University Press
record_format MEDLINE/PubMed
spelling pubmed-96438982022-11-14 Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma Zhang, Ziyuan Liu, Juan Xiao, Min Zhang, Quanfeng Liu, Zhonghua Liu, Meiyan Zhang, Peng Zeng, Youlin Nano Res Research Article The activation of the stimulating factor of the interferon gene (STING) pathway can enhance the immune response within the tumor. Cyclic diguanylate monophosphate (c-di-GMP) is a negatively charged, hydrophilic STING agonist, however, its effectiveness is limited due to the poor membrane permeability and low bioavailability. Herein, we introduced KL-7 peptide derived from Aβ amyloid fibrils that can self-assemble to form nanotubes to load and deliver c-di-GMP, which significantly enhanced c-di-GMP’s effectiveness and then exhibited a robust “in situ immunity” to kill melanoma cells. KL-7 peptide nanotube, also called PNT, was loaded with negatively charged c-di-GMP via electrostatic interaction, which prepared a nanocomposite named c-di-GMP-PNT. Treatment of RAW 264.7 cells (leukemia cells in mouse macrophage) with c-di-GMP-PNT markedly stimulated the secretion of IL-6 and INF-β along with phospho-STING (Ser365) protein expression, indicating the activation of the STING pathway. In the unilateral flank B16-F10 (murine melanoma cells) tumor-bearing mouse model, compared to PNT and c-di-GMP, c-di-GMP-PNT can promote the expression of INF-β, TNF-α, IL-6, and IL-1β. At the same time, up-regulated CD4 and CD8 active T cells kill tumors and enhance the immune response in tumor tissues, resulting in significant inhibition of tumor growth in tumor-bearing mice. More importantly, in a bilateral flank B16-F10 tumor model, both primary and distant tumor growth can also be significantly inhibited by c-di-GMP-PNT. Moreover, c-di-GMP-PNT demonstrated no obvious biological toxicity on the main organs (heart, liver, spleen, lung, and kidney) and biochemical indexes of mice. In summary, our study provides a strategy to overcome the barriers of free c-di-GMP in the tumor microenvironment and c-di-GMP-PNT may be an attractive nanomaterial for anti-tumor immunity. [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material (synthesis and characterization of KL-7 peptide; the encapsulation rate and cumulative release rate of c-di-GMP-PNT; cytotoxicity of PNT, c-di-GMP, and c-di-GMP-PNT; anti-tumor effect of c-di-GMP-PNT (equivalent to 1 and 5 µg c-di-GMP per mouse); representative immunofluorescence images; and biosafety analysis) is available in the online version of this article at 10.1007/s12274-022-5102-z. Tsinghua University Press 2022-11-09 2023 /pmc/articles/PMC9643898/ /pubmed/36405984 http://dx.doi.org/10.1007/s12274-022-5102-z Text en © Tsinghua University Press 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research Article
Zhang, Ziyuan
Liu, Juan
Xiao, Min
Zhang, Quanfeng
Liu, Zhonghua
Liu, Meiyan
Zhang, Peng
Zeng, Youlin
Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma
title Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma
title_full Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma
title_fullStr Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma
title_full_unstemmed Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma
title_short Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma
title_sort peptide nanotube loaded with a sting agonist, c-di-gmp, enhance cancer immunotherapy against melanoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643898/
https://www.ncbi.nlm.nih.gov/pubmed/36405984
http://dx.doi.org/10.1007/s12274-022-5102-z
work_keys_str_mv AT zhangziyuan peptidenanotubeloadedwithastingagonistcdigmpenhancecancerimmunotherapyagainstmelanoma
AT liujuan peptidenanotubeloadedwithastingagonistcdigmpenhancecancerimmunotherapyagainstmelanoma
AT xiaomin peptidenanotubeloadedwithastingagonistcdigmpenhancecancerimmunotherapyagainstmelanoma
AT zhangquanfeng peptidenanotubeloadedwithastingagonistcdigmpenhancecancerimmunotherapyagainstmelanoma
AT liuzhonghua peptidenanotubeloadedwithastingagonistcdigmpenhancecancerimmunotherapyagainstmelanoma
AT liumeiyan peptidenanotubeloadedwithastingagonistcdigmpenhancecancerimmunotherapyagainstmelanoma
AT zhangpeng peptidenanotubeloadedwithastingagonistcdigmpenhancecancerimmunotherapyagainstmelanoma
AT zengyoulin peptidenanotubeloadedwithastingagonistcdigmpenhancecancerimmunotherapyagainstmelanoma